SCHEMBL6355704

SCHEMBL6355704

CC(C)[C@@H]1C(=O)N(CC(=O)O)C(c2ccccc2)=CN1C(=O)c1ccncc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.38
HTT P42858 1/20 0.38
MAPK1 P28482 2/20 0.36
ROCK2 O75116 1/20 0.36
RPS6KA5 O75582 1/20 0.36
MAP4K4 O95819 1/20 0.36
CDK1 P06493 1/20 0.36
CSF1R P07333 1/20 0.36
PRKACA P17612 1/20 0.36
FLT1 P17948 1/20 0.36
RPS6KB1 P23443 1/20 0.36
CDK2 P24941 1/20 0.36
AKT1 P31749 1/20 0.36
FLT4 P35916 1/20 0.36
KDR P35968 1/20 0.36
FLT3 P36888 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
RPS6KA3 P51812 1/20 0.36
PRKX P51817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6357403 1.00 PKM (0.38) PKMHTTMAPK1ROCK2RPS6KA5
SCHEMBL6357399 1.00 PKM (0.38) PKMHTTMAPK1ROCK2RPS6KA5
SCHEMBL6349771 0.92 CA12 (0.36) PIK3CDKMT2AMEN1ALDH1A1CA12
SCHEMBL6348100 0.92 CA12 (0.36) PIK3CDKMT2AMEN1ALDH1A1CA12
SCHEMBL6348102 0.92 CA12 (0.36) PIK3CDKMT2AMEN1ALDH1A1CA12
SCHEMBL6348150 0.89 L3MBTL1 (0.40) PIK3CDRIPK1ALDH1A1PLOD2MAPT
SCHEMBL6348151 0.89 L3MBTL1 (0.40) PIK3CDRIPK1ALDH1A1PLOD2MAPT
SCHEMBL6346705 0.89 L3MBTL1 (0.40) PIK3CDRIPK1ALDH1A1PLOD2MAPT
SCHEMBL6346920 0.87 MDM2 (0.38) SMN1; SMN2ALDH1A1CYP2C19CYP1A2CYP2C9
SCHEMBL6346925 0.87 MDM2 (0.38) SMN1; SMN2ALDH1A1CYP2C19CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 PKM 2577/4885HTT 1316/4885MAPK1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.